Navigation Links
Key immune cell may play role in lung cancer susceptibility
Date:9/21/2012

Why do many heavy smokers evade lung cancer while others who have never lit up die of the disease? The question has vexed scientists for decades.

Now, new research at Washington University School of Medicine in St. Louis suggests a key immune cell may play a role in lung cancer susceptibility. Working in mice, they found evidence that the genetic diversity in natural killer cells, which typically seek out and destroy tumor cells, contributes to whether or not the animals develop lung cancer.

The research is published in September in Cancer Research.

"Overall, humans are genetically very similar but their immune systems are incredibly diverse," explains senior author Alexander Krupnick, MD, a thoracic surgeon at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. "Our findings add to the growing body of evidence suggesting that innate differences in immunity may determine not only a person's susceptibility to colds but also to lung cancer."

Based on the findings in mice, Krupnick says he and his colleagues now are studying whether humans have a similar genetic diversity in their natural killer cells. As part of a new clinical study, they're analyzing the blood of heavy smokers with and without lung cancer and never-smokers with and without lung cancer to look for differences.

"We want to know whether heavy smokers who don't get lung cancer have natural killer cells that are somehow better at destroying newly developing lung cancer cells," says Krupnick, associate professor of surgery. "And, by comparison, do patients who have never smoked but develop lung cancer have weak natural killer cells?"

For the mouse study, the scientists evaluated three groups of mice with varying susceptibilities to lung tumors. After the mice were exposed to a carcinogen that causes lung cancer, one group readily developed the disease while another showed little evidence of the tumors. A third group experienced moderate tumor growth.

When the researchers depleted natural killers cells from the mice using an antibody, those that had been resistant to lung cancer developed large, aggressive tumors.

Further, in mice susceptible to lung cancer, the scientists showed that manipulating the immune system with a bone marrow transplant could significantly block the development of lung cancer. Their studies indicate that natural killer cells, not other types of immune cells like T cells or inflammatory cells, are responsible for this phenomenon.

In other types of cancers, including those of the breast, colon and prostate, T cells are capable of destroying tumor cells. But in lung cancer, scientists suspect that T cells become inactivated, which may give natural killer cells a more prominent role.

The researchers also traced the genetic diversity of the natural killer cells in the mice to a region of chromosome 6, which includes numerous genes that influence the effectiveness of these cells.

Moving forward, Krupnick and his team want to learn whether natural killer cells influence lung cancer susceptibility in people. "We need to identify those patients who are resistant to lung cancer and ask, 'What is unique about their natural killer cells are they more potent or do they produce more of them than people with lung cancer?' The answer will determine our next steps."


'/>"/>

Contact: Caroline Arbanas
arbanasc@wustl.edu
314-286-0109
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. Feeding microbials to chickens leads to mysterious immune response
2. Researchers improve gene therapy technique for children with immune disorder
3. New grant awards aim to prevent autoimmune diseases
4. Immune system protein could explain pancreatitis
5. Cancer turns off important immune cells, complicating experimental vaccine therapies
6. Trudeau researchers identify unforeseen regulation of the anti-bacterial immune response
7. In war with superbugs, Cedars-Sinai researchers see new weapon: Immune-boosting vitamin
8. New Immune-Deficiency Illness Emerging in East Asia
9. Immune responses can be generated locally within human melanoma skin metastases
10. Mount Sinai researchers discover new target for vaccine development in abundant immune cells
11. Mouse With Human-Like Immune System Could Advance AIDS Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... A stressful work ... work can also decrease overall productivity and performance in the workplace. The goal of ... During the last few weeks of April, Clearview Resolution Services will be shutting down ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... modern procedure that achieves results in a fraction of the time as traditional ... NV, with Significance Dental Specialists, now offers this revolutionary treatment with or without ...
(Date:4/25/2017)... ... , ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care ... on preventative care with all my patients to alleviate possible future issues. I am pleased ... contact my office and my trained staff will assist you in any way possible.” , ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., ... of its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), ... and effective management of complex spine deformity cases, particularly in children. , GSO’s ...
(Date:4/24/2017)... Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... their efforts to encourage sustainability, innovate new strategies to reduce waste, and support renewable ... herbal remedy provider. They look to nature to find solutions for health issues, and ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition ... Addressing Production Complexities Through Risk Management and Quality by ... ... Market Prospects: Overcoming Production Complexities Through Risk Management and ... current trends in the global biosimilars market, with a ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
Breaking Medicine Technology: